Free Trial
NYSEAMERICAN:AST

Asterias Biotherapeutics (AST) Stock Price, News & Analysis

Asterias Biotherapeutics logo
$0.0020 0.00 (0.00%)
As of 07/10/2019

About Asterias Biotherapeutics Stock (NYSEAMERICAN:AST)

Key Stats

Today's Range
$0.0020
$0.0020
50-Day Range
N/A
52-Week Range
$0.51
$2.05
Volume
1,000 shs
Average Volume
136,653 shs
Market Capitalization
$111,318.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.

Remove Ads
Receive AST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Asterias Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

AST Stock News Headlines

ARTV Artiva Biotherapeutics, Inc.
Trump Allies Confirm Exec Order 14024 Triggers Dollar Collapse
Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.
CLDI Calidi Biotherapeutics, Inc.
Protalix BioTherapeutics Inc PLX
See More Headlines

AST Stock Analysis - Frequently Asked Questions

Asterias Biotherapeutics' stock was trading at $0.0020 at the beginning of 2025. Since then, AST shares have increased by 0.0% and is now trading at $0.0020.
View the best growth stocks for 2025 here
.

Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) released its quarterly earnings results on Tuesday, March, 28th. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.01. The biotechnology company earned $1.75 million during the quarter, compared to analysts' expectations of $2.81 million.

Shares of AST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Asterias Biotherapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CorMedix (CRMD), Synergy Pharmaceuticals (SGYP), 22nd Century Group (XXII), Amarin (AMRN), Gilead Sciences (GILD) and Progenics Pharmaceuticals (PGNX).

Company Calendar

Last Earnings
3/28/2017
Today
4/01/2025

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:AST
Previous Symbol
NYSEMKT:AST
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$111,318.00
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report

This page (NYSEAMERICAN:AST) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners